Diazoles (including Hydrogenated) Patents (Class 514/94)
  • Patent number: 10323052
    Abstract: Preparation, in-vitro and in vivo characterization of novel forms of (1-hydroxy-2-imidazol-1-yl-1-phosphono-ethyl) phosphonic acid, suitable for pharmaceutical compositions in drug delivery systems for humans.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: June 18, 2019
    Assignee: GRUNENTHAL GMBH
    Inventors: Mazen Hanna, Ning Shan, Miranda L. Cheney, David R. Weyna, Raymond K. Houck
  • Patent number: 10265332
    Abstract: Oral dosage forms of osteoclast inhibitors, such as zoledronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as osteoarthritis.
    Type: Grant
    Filed: April 16, 2018
    Date of Patent: April 23, 2019
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Patent number: 10195218
    Abstract: Preparation, in-vitro and in vivo characterization of novel forms of (1-hydroxy-2-imidazol-1-yl-1-phosphono-ethyl) phosphonic acid, suitable for pharmaceutical compositions in drug delivery systems for humans.
    Type: Grant
    Filed: May 31, 2017
    Date of Patent: February 5, 2019
    Assignee: GRUNENTHAL GMBH
    Inventor: Mazen Hanna
  • Patent number: 10173986
    Abstract: Methods for the safe administration of imidazole or imidazolium compounds such as zoledronic acid, and conditions that may be treated by these methods, are described herein.
    Type: Grant
    Filed: May 25, 2017
    Date of Patent: January 8, 2019
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Patent number: 10141118
    Abstract: A carrier system carries a dye (A) and a co-adsorbent (B) represented by general formula (1): wherein, ring A represents a 5- or 6-membered heterocycle and may further be fused; a hydrogen atom in the ring A may be replaced by a halogen atom, a cyano group, a nitro group, an —OR2 group, an —SR2 group, or a hydrocarbon group that may have a substituent; Z represents a divalent aliphatic hydrocarbon group that is interrupted zero to three times by —O— etc.; Z1 represents a divalent aromatic group; R1 represents a carboxylic acid group, a sulfonic acid group, a phosphoric acid group, or a phosphonic acid group; R2 and R3 each represent a hydrogen atom or a hydrocarbon group that may have a substituent; Anm? represents an m-valent anion; m represents an integer of 1 or 2; and p represents a coefficient for keeping the electrical charge neutral.
    Type: Grant
    Filed: January 26, 2015
    Date of Patent: November 27, 2018
    Assignee: ADEKA CORPORATION
    Inventors: Yohei Aoyama, Kensaku Akimoto
  • Patent number: 10093691
    Abstract: Preparation and in vitro and in vivo characterization of novel forms of active pharmaceutical ingredients, suitable for pharmaceutical compositions in drug delivery systems for humans.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: October 9, 2018
    Assignee: GRUNENTHAL GMBH
    Inventors: Mazen Hanna, Ning Shan, Miranda L. Cheney, David R. Weyna, Raymond Houck
  • Patent number: 10077280
    Abstract: Gold(I) complex with mixed ligands as an anticancer agent. The gold(I) ion is coordinated to a dithiocarbamate ligand and a phosphorus-containing ligand (e.g. phosphines). Also described are a pharmaceutical composition incorporating the gold(I) complex, a methods of synthesizing the gold(I) complex, and a method for treating cancer.
    Type: Grant
    Filed: November 15, 2016
    Date of Patent: September 18, 2018
    Assignees: King Fahd University of Petroleum and Minerals, King Saud University
    Inventors: Said S. Al-Jaroudi, Ali Alhoshani, Muhammad Altaf, Anvarhusein Abdulkadir Isab
  • Patent number: 10016446
    Abstract: Oral dosage forms of osteoclast inhibitors, such as nitrogen-containing bisphosphonates, such as zoledronic acid in an acid or a salt form, or in a molecular complex can be used to treat or alleviate pain or related conditions, such as treating pain associated with Paget's disease of bone.
    Type: Grant
    Filed: January 10, 2017
    Date of Patent: July 10, 2018
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Patent number: 9956237
    Abstract: Oral dosage forms of osteoclast inhibitors, such as zoledronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as knee pain.
    Type: Grant
    Filed: June 15, 2017
    Date of Patent: May 1, 2018
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Patent number: 9938263
    Abstract: There are provided, inner alia, compounds and methods for lowering total AB peptide production by inhibiting the catalytic activity of gamma-secretase. Since all of the major AB peptide variants, including the pathogenic AB42 as known in the art, are ultimately generated by gamma-secretase-mediated proteolysis of APP-C99 (i.e., the beta-secretase-mediated cleavage product of the amyloid protein precursor IAPPI), one approach to therapeutic intervention (e.g., intervention in Alzheimer's Disease, AD) relates to lowering total AB peptide production by inhibiting the catalytic activity of gamma-secretase.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: April 10, 2018
    Assignees: The General Hospital Corporation, The Regents of the University of California
    Inventors: Rudolph E. Tanzi, Steven L. Wagner, Soan Cheng, William C. Mobley
  • Patent number: 9717747
    Abstract: Oral dosage forms of osteoclast inhibitors, such as nitrogen-containing bisphosphonates, such as zoledronic acid, can be used to treat or alleviate pain or related conditions.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: August 1, 2017
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventors: Herriot Tabuteau, Graeme Jones
  • Patent number: 9561226
    Abstract: The invention provides a method of inhibiting the effects of platelet activating factor (PAF). For instance, a disease or condition mediated by PAF (particularly inflammation) can be treated or platelet aggregation can be inhibited. The invention also provides a method of inhibiting the production and/or release of interleukin 8 (IL-8) by cells. The effects of PAF and the production and/or release of IL-8 are inhibited according to the invention by a compound of the formula: wherein R1 and R2 are defined in the application, or a physiologically-acceptable salt thereof. The invention also provides pharmaceutical compositions comprising these compounds.
    Type: Grant
    Filed: August 8, 2014
    Date of Patent: February 7, 2017
    Assignee: Ampio Pharmaceuticals, Inc.
    Inventors: David Bar-Or, C. Gerald Curtis, Nagaraja K. R. Rao, Greg Thomas
  • Patent number: 9351955
    Abstract: The present invention discloses compounds according to Formula I: wherein R1 is as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment cystic fibrosis by administering a compound of the invention.
    Type: Grant
    Filed: July 24, 2015
    Date of Patent: May 31, 2016
    Assignee: Galapagos NV
    Inventors: Steven Emiel Van Der Plas, Hans Kelgtermans, Sébastien Jean Jacques Cédric Dropsit Montovert, Sébastien Laurent Xavier Martina, Martin James Inglis Andrews
  • Patent number: 9334296
    Abstract: Preparation, in-vitro and in vivo characterization of novel forms of (1-hydroxy-2-imidazol-1-yl-1-phosphono-ethyl)phosphonic acid, suitable for pharmaceutical compositions in drug delivery systems for humans.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: May 10, 2016
    Assignee: THAR PHARMACEUTICALS, INC.
    Inventors: Mazen Hanna, Ning Shan, Miranda L. Cheney, David R. Weyna, Raymond K. Houck
  • Patent number: 9254299
    Abstract: Cancer can be treated by administration of TH-302 in combination with a Chk1 inhibitor.
    Type: Grant
    Filed: December 20, 2012
    Date of Patent: February 9, 2016
    Assignee: Threshold Pharmaceuticals, Inc.
    Inventors: Charles Hart, Fanying Meng, Jessica Sun
  • Patent number: 9226932
    Abstract: Phosphoramidate alkylator prodrugs can be used to treat cancer when administered alone or in combination with one or more anti-neoplastic agents.
    Type: Grant
    Filed: December 10, 2013
    Date of Patent: January 5, 2016
    Assignee: Threshold Pharmaceuticals, Inc.
    Inventors: Mark Matteucci, Jian-Xin Duan, Hailong Jiao
  • Patent number: 9149462
    Abstract: The present invention relates to pyrazole amide derivatives pharmaceutical compositions containing these compounds and to their use in therapy.
    Type: Grant
    Filed: October 19, 2011
    Date of Patent: October 6, 2015
    Assignee: Glaxo Group Limited
    Inventors: Anthony William James Cooper, Paul Martin Gore, David House
  • Patent number: 9137986
    Abstract: The present invention relates to a mixed agrochemical emulsion composition comprising: an organic phosphorous pesticide represented by formula (I) (wherein, R1 represents a C1-4 linear or branched alkyl group; R2 represents a C1-4 linear or branched alkyl group; R3 represents a nitrogenated heterocyclic group which may have a substituent or a group —OR4 (wherein R4 represents a nitrogenated heterocyclic group which may have a substituent; and X and Y each independently represent an oxygen atom or a sulfur atom, wherein Y is a sulfur atom when X is an oxygen atom, and Y is an oxygen atom when X is a sulfur atom); chloropicrin; and a nonionic surfactant. The composition has excellent storage stability and excellent emulsifying properties in water and can be sprayed and applied conveniently by diluting the composition with water, in spite of a fact that both chloropicrin and the organic phosphorous pesticide, which are effective for the control of pests, are contained.
    Type: Grant
    Filed: October 3, 2012
    Date of Patent: September 22, 2015
    Assignee: ISHIHARA SANGYO KAISHA, LTD.
    Inventors: Mikio Sekiguchi, Takao Awazu
  • Publication number: 20150148312
    Abstract: Oral dosage forms of osteoclast inhibitors, such as nitrogen-containing bisphosphonates, can be used to treat or alleviate pain or related conditions.
    Type: Application
    Filed: January 23, 2015
    Publication date: May 28, 2015
    Inventors: Herriot Tabuteau, Graeme Jones
  • Publication number: 20150141374
    Abstract: Oral dosage forms of osteoclast inhibitors, such as nitrogen-containing bisphosphonates, can be used to treat or alleviate pain or related conditions.
    Type: Application
    Filed: January 28, 2015
    Publication date: May 21, 2015
    Inventors: Herriot Tabuteau, Graeme Jones
  • Publication number: 20150141373
    Abstract: Oral dosage forms of osteoclast inhibitors, such as nitrogen-containing bisphosphonates, can be used to treat or alleviate pain or related conditions.
    Type: Application
    Filed: January 28, 2015
    Publication date: May 21, 2015
    Inventors: Herriot Tabuteau, Graeme Jones
  • Publication number: 20150133403
    Abstract: Oral dosage forms of osteoclast inhibitors, such as nitrogen-containing bisphosphonates, can be used to treat or alleviate pain or related conditions.
    Type: Application
    Filed: January 26, 2015
    Publication date: May 14, 2015
    Inventors: Herriot Tabuteau, Graeme Jones
  • Publication number: 20150126475
    Abstract: To provide a pesticidal composition having a broad pesticidal spectrum, having high activity and having a long lasting effect. A pesticidal composition comprising as active ingredients at least one organic phosphorus compound (A) selected from the group consisting of fosthiazate and imicyafos and at least one compound (B) selected from the group consisting of clothianidin, dinotefuran, thiamethoxam, tefluthrin, silafluofen, chlorfluazuron, flufenoxuron and teflubenzuron (excluding a combination of fosthiazate and tefluthrin).
    Type: Application
    Filed: July 2, 2013
    Publication date: May 7, 2015
    Applicant: ISHIHARA SANGYO KAISHA, LTD.
    Inventor: Hideshi Yoshimura
  • Publication number: 20150119365
    Abstract: The present invention provides for novel compounds of Formulas I and II and pharmaceutically acceptable salts and co-crystals thereof which have glucokinsae activator activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucokinase activator is indicated, including Type 1 and 2 diabetes, impaired glucose tolerance, insulin resistance and hyperglycemia. The present invention also provides for processes of making the compounds of Formulas I and II, including salts and co-crystals thereof, and pharmaceutical compositions comprising the same.
    Type: Application
    Filed: December 29, 2014
    Publication date: April 30, 2015
    Inventors: Feng Tian, Qun Dang, G. Sridhar Prasad, Wenyu Li, Brett C. Bookser, Nicholas Brian Raffaele, Mark D. Erion
  • Patent number: 9012432
    Abstract: A combination therapy for treating osteoarthritis is disclosed. The combination therapy includes the co-administration of a steroid and Zoledronic Acid. The coadministration of a steroid decreases the production of cytokines, and, therefore, decreases the pro-inflammatory effects of Zoledronic Acid. The co-administration of Zoledronic Acid with steroids treats osteoarthritis, and helps to prevent the onset of osteoarthritis in patients at risk for osteoarthritis.
    Type: Grant
    Filed: March 8, 2013
    Date of Patent: April 21, 2015
    Assignee: Levolta Pharmaceuticals, Inc.
    Inventor: Ketan Desai
  • Publication number: 20150105352
    Abstract: The invention relates to the use of a hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor and of a farnesyl-pyrophosphate synthase inhibitor, or of one of their associated physiologically acceptable salts, in the preparation of a composition, particularly a pharmaceutical composition, for use in the treatment of human or animal, pathological or nonpathological situations related to the accumulation and/or the persistence of prenylated proteins in cells, such as during progeria (Hutchinson-Gilford syndrome), restrictive dermopathy or physiological ageing.
    Type: Application
    Filed: December 18, 2014
    Publication date: April 16, 2015
    Inventors: Nicolas LEVY, Pierre CAU, Carlos LOPEZ-OTIN
  • Patent number: 8980294
    Abstract: Ready-to-use foamable pesticide compositions that contain a particulate pesticide suspended therein and applicators for dispensing such compositions. Methods for treating pests such as arthropods by contacting pests with such compositions are also provided.
    Type: Grant
    Filed: April 28, 2010
    Date of Patent: March 17, 2015
    Assignee: BASF Corporation
    Inventors: Terrence R. Burke, Henry Wayne Moran, Jonathan D. Berger, James H. Cink
  • Patent number: 8980868
    Abstract: Novel solution complexes of zoledronic acid are described which give rise to improved properties of zoledronic acid. The invention includes aqueous solution and molecular complexes of zoledronic acid with and optical isomers of asparagine, histidine, arginine and proline as well as pharmaceutical complexes containing them and methods of treatment using them.
    Type: Grant
    Filed: July 30, 2010
    Date of Patent: March 17, 2015
    Assignee: Thar Pharmaceuticals, Inc.
    Inventors: Mazen Hanna, Ning Shan, Miranda Cheney, David Weyna
  • Publication number: 20150065466
    Abstract: The present invention generally concerns particular methods and compositions for antimicrobial therapy. In particular embodiments, the compositions target DXR. In some cases, the antimicrobial agent comprises an electron-deficient hydrophobic group that has interacts with Trp211 of DXR. In specific embodiments, the compound contains electron-deficient heterocyclic rings that specifically interact with the electron-rich indole ring of Trp211. In certain aspects, the compositions comprise a phosphate group, a pyridine group, and a hydroxymate group.
    Type: Application
    Filed: April 18, 2013
    Publication date: March 5, 2015
    Inventor: Yongcheng Song
  • Publication number: 20150057250
    Abstract: Oral dosage forms of bisphosphonate compounds, such as zoledronic acid, can be used to treat or alleviate pain or related conditions.
    Type: Application
    Filed: November 7, 2014
    Publication date: February 26, 2015
    Inventor: Herriot Tabuteau
  • Patent number: 8962599
    Abstract: Therapeutic compositions comprising substituted imidazole or imidazolium compounds may be used for a number of medical purposes, such as treatment of undesirable conditions or diseases, including disease or conditions related to bone, cancer, and/or pain.
    Type: Grant
    Filed: September 9, 2014
    Date of Patent: February 24, 2015
    Assignee: Antecip Bioventures II LLC
    Inventor: Herriot Tabuteau
  • Publication number: 20150051175
    Abstract: Oral dosage forms of bisphosphonate compounds, such as zoledronic acid, can be used to treat or alleviate pain or related conditions.
    Type: Application
    Filed: October 31, 2014
    Publication date: February 19, 2015
    Inventor: Herriot Tabuteau
  • Publication number: 20150045327
    Abstract: The present invention discloses compounds according to Formula I: wherein R1 is as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment cystic fibrosis by administering a compound of the invention.
    Type: Application
    Filed: August 5, 2014
    Publication date: February 12, 2015
    Inventors: Steven Emiel VAN DER PLAS, Hans KELGTERMANS, Sébastien Jean Jacques Cédric DROPSIT MONTOVER, Sébastien Laurent Xavier MARTINA, Martin James Inglis ANDREWS
  • Patent number: 8946275
    Abstract: Cancer can be treated by administration of a hypoxia-activated prodrug, such as TH-302, alone or in combination with other anticancer agents and/or radiation therapy. In combination therapy, the hypoxia-activated prodrug and another anti-cancer agent or radiation therapy may be administered within the same 24-hour period, and administration of the hypoxia-activated prodrug may be completed prior to beginning administration of the other anticancer agent or radiation therapy.
    Type: Grant
    Filed: October 21, 2009
    Date of Patent: February 3, 2015
    Assignee: Threshold Pharmaceuticals, Inc.
    Inventors: Stewart Kroll, Mark Matteucci, Charles P. Hart, Jian-Xin Duan, Karen Curd
  • Publication number: 20150031649
    Abstract: A combination therapy for treating osteoarthritis is disclosed. The combination therapy includes the co-administration of a steroid and Zoledronic Acid. The coadministration of a steroid decreases the production of cytokines, and, therefore, decreases the pro-inflammatory effects of Zoledronic Acid. The co-administration of Zoledronic Acid with steroids treats osteoarthritis, and helps to prevent the onset of osteoarthritis in patients at risk for osteoarthritis.
    Type: Application
    Filed: October 14, 2014
    Publication date: January 29, 2015
    Applicant: Voltarra Pharmaceuticals, Inc.
    Inventor: Ketan Desai
  • Patent number: 8940927
    Abstract: The present invention provides for novel compounds of Formulas I and II and pharmaceutically acceptable salts and co-crystals thereof which have glucokinase activator activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucokinase activator is indicated, including Type 1 and 2 diabetes, impaired glucose tolerance, insulin resistance and hyperglycemia. The present invention also provides for processes of making the compounds of Formulas I and II, including salts and co-crystals thereof, and pharmaceutical compositions comprising the same.
    Type: Grant
    Filed: May 25, 2011
    Date of Patent: January 27, 2015
    Assignee: Metabasis Therapeutics, Inc.
    Inventors: Feng Tian, Qun Dang, G. Sridhar Prasad, Wenyu Li, Brett C. Bookser, Nicholas Brian Raffaele, Mark D. Erion
  • Publication number: 20150023955
    Abstract: The present invention discloses novel agents and methods for diagnosis and treatment of melanoma. Also disclosed are related arrays, kits, and screening methods.
    Type: Application
    Filed: September 15, 2014
    Publication date: January 22, 2015
    Applicant: THE ROCKEFELLER UNIVERSITY
    Inventors: Sohail Tavazoie, Nora Pencheva
  • Publication number: 20150017267
    Abstract: The present invention relates to the prevention, reduction, inhibition and reversal of pain and inflammation in a non-human mammal by administration of an inhibitor of soluble epoxide hydrolase, as sole active agent or co-administered with other active agents.
    Type: Application
    Filed: March 5, 2013
    Publication date: January 15, 2015
    Applicant: The Regents of the University of California
    Inventors: Alonso G.P. Guedes, Bruce D. Hammock, Christophe Morisseau
  • Patent number: 8933057
    Abstract: Preparation, in-vitro and in vivo characterization of novel forms of (1-hydroxy-2-imidazol-1-yl-1-phosphono-ethyl) phosphonic acid, suitable for pharmaceutical compositions in drug delivery systems for humans.
    Type: Grant
    Filed: February 13, 2013
    Date of Patent: January 13, 2015
    Assignee: Thar Pharmaceuticals, Inc.
    Inventors: Mazen Hanna, Ning Shan, Miranda L. Cheney, David R. Weyna, Raymond K. Houck
  • Publication number: 20150005261
    Abstract: The invention provides methods for treating fibrosis, as well as methods for modulating mitochondrial peroxide production in a cell, and methods for modulating the import of Rac1 into the mitochondria of a cell.
    Type: Application
    Filed: April 25, 2014
    Publication date: January 1, 2015
    Applicant: University of Iowa Research Foundation
    Inventors: Raymond J. Hohl, A. Brent Carter
  • Publication number: 20150005263
    Abstract: Cancer can be treated by administration of TH-302 in combination with a Chk1 inhibitor.
    Type: Application
    Filed: December 20, 2012
    Publication date: January 1, 2015
    Inventors: Charles Hart, Fanying Meng, Jessica Sun
  • Publication number: 20150005262
    Abstract: Cancer is treated by administration of a hypoxia activated prodrug in combination with an mTOR inhibitor.
    Type: Application
    Filed: December 20, 2012
    Publication date: January 1, 2015
    Inventors: Charles Hart, Jessica Sun, Fanying Meng
  • Publication number: 20150005264
    Abstract: CA-IX levels are predictive of the probability that a cancer patient will respond favorably to cancer therapy involving administration of a hypoxia-activated prodrug. In a first aspect, the present invention provides a method for treating cancer comprising the steps of measuring CA-IX levels in a sample isolated from the patient, and administering a hypoxia-activated prodrug only if the CA-IX level measured is equal to or greater than about 30 pg/mL (e.g. 28.8 pg/mL) CA-IX protein in a serum sample, as may be measured, for example or without limitation, using an ELISA. In one embodiment, a HAP is administered if the measured CA-IX level is equal to or greater than about 75 pg/mL (e.g. 77.1 pg/mL) protein in a serum sample. Thus, in one embodiment, the CA-IX level is measured based on the amount of CA-IX protein in a serum sample.
    Type: Application
    Filed: January 30, 2013
    Publication date: January 1, 2015
    Inventor: Charles Hart
  • Publication number: 20140356814
    Abstract: The present invention relates to a dental implant having an enhanced early stability and a method for manufacturing same, and more specifically to a dental implant and a method for manufacturing same which assure early stability and fixation power of an implant by suppressing early osteolysis after an implant procedure, and allowing better bone coherence of the implant surface during an osteogenic period by controlling the speed of bone remodeling.
    Type: Application
    Filed: October 4, 2012
    Publication date: December 4, 2014
    Inventors: Su Kyoung Kim, Eun Jung Kang, Ju Dong Song, Tae Gwan Eom, Kyoo Ok Choi
  • Patent number: 8901106
    Abstract: Imidazole prodrugs, pharmaceutically acceptable salts, or isomers thereof, of the invention are disclosed, which are useful as modulators of the activity of liver X receptors (LXR). Pharmaceutical compositions containing the compounds and methods of using the compounds are also disclosed.
    Type: Grant
    Filed: March 26, 2012
    Date of Patent: December 2, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ellen K. Kick, Michael J. Hageman, Victor R. Guarino, Ching-Chiang Su, Chenkou Wei, Jayakumar S. Warrier, Satheesh Nair
  • Publication number: 20140348916
    Abstract: Disclosed herein are methods of treating or preventing pain. Typically, a pharmaceutical composition having a therapeutically effective amount of the zoledronic acid is administered to a mammal suffering from pain. The pharmaceutical composition may further comprise an enhancer, which can be a medium chain fatty acid salt, an ester, an ether, or a derivative of a medium chain fatty acid and can have a carbon chain length of from about 4 to about 20 carbon atoms.
    Type: Application
    Filed: August 11, 2014
    Publication date: November 27, 2014
    Inventor: Herriot Tabuteau
  • Publication number: 20140349974
    Abstract: Treatment of pain and related conditions with oral dosage forms of zoledronic acid is described herein.
    Type: Application
    Filed: August 12, 2014
    Publication date: November 27, 2014
    Inventor: Herriot Tabuteau
  • Patent number: 8883203
    Abstract: The invention relates to a pharmaceutical composition and oral dosage forms comprising a bisphosphonate in combination with an enhancer to enhance intestinal delivery of the bisphosphonate to the underlying circulation. Preferably, the enhancer is a medium chain fatty acid or a medium chain fatty acid derivative having a carbon chain length of from 6 to 20 carbon atoms, and the solid oral dosage form is a controlled release dosage form such as a delayed release dosage form.
    Type: Grant
    Filed: April 26, 2010
    Date of Patent: November 11, 2014
    Assignee: Merrion Research III Limited
    Inventor: Thomas W. I. Leonard
  • Publication number: 20140329773
    Abstract: Oral dosage forms of bisphosphonate compounds, such as zoledronic acid, can be used to treat or alleviate pain or related conditions.
    Type: Application
    Filed: July 21, 2014
    Publication date: November 6, 2014
    Inventor: Herriot Tabuteau
  • Publication number: 20140322231
    Abstract: Methods for treating neurodegeneration, e.g., sensorineural hearing loss, or a demyelinating disease, using bisphosphonates, ERK kinase inhibitors, and osteoprotegerin (OPG) proteins or nucleic acids.
    Type: Application
    Filed: March 18, 2014
    Publication date: October 30, 2014
    Applicant: MASSACHUSETTS EYE AND EAR INFIRMARY
    Inventors: Konstantina Stankovic, Michael McKenna, Shyan-Yuan Kao, Albert Edge